368 results on '"Lequerré, Thierry"'
Search Results
2. Arrêt du tabac, soins bucco-dentaires et devenir des rhumatismes inflammatoires
3. Points to consider for unmet needs in axial spondyloarthritis. Proceedings of the French spondyloArthritiS Taskforce workshop
4. Clinical impact of a personalized pharmaceutical plan on opioid management in non-cancer pain: a pilot study
5. L’uvéite dans les rachialgies inflammatoires récentes. Données à cinq ans de la cohorte nationale française prospective DESIR
6. Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
7. Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
8. Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
9. Uveitis occurrence in early inflammatory back pain. Five years data from the prospective French nationwide DESIR cohort
10. Microbiological diagnosis of suspected vertebral osteomyelitis with a focus on the yield of percutaneous needle biopsy: a 10-year cohort study
11. Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR)
12. Association Between the Number of Comorbidities and the Risk of a Serious Infection in Rheumatoid Arthritis Treated by a First Biologic Agent
13. Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
14. Predictors of treatment response in rheumatoid arthritis
15. Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis
16. Facteurs prédictifs de réponses dans la polyarthrite rhumatoïde
17. Conséquences du tabac sur le devenir de la polyarthrite rhumatoïde
18. Soluble vascular endothelial (VE) cadherin and autoantibodies to VE-cadherin in rheumatoid arthritis patients treated with etanercept or adalimumab
19. Lupus With Erosive Arthritis: A Singular Joint Phenotype of Lupus or Rhupus?
20. Rheumatoid arthritis, insulin resistance, and diabetes
21. Polyarthrite rhumatoïde, insulino-résistance et diabète
22. Le passage d’un anticorps anti-TNFα vers l’étanercept est plus bénéfique que l’inverse dans la polyarthrite rhumatoïde : étude rétrospective observationnelle sur 72 patients
23. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers
24. Chapitre 58 - Arthrites inflammatoires
25. Biologic targeted therapies in pediatric rheumatology
26. Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma
27. Atteinte articulaire de la sarcoïdose et risque accru de survenue d’une spondyloarthrite. Étude cas-témoins monocentrique rétrospective
28. 08.02 Alpha-enolase promotes pro-inflammatory phenotype of monocytes-derived macrophages in vitro
29. Évaluation de l’impact des recommandations de la Haute Autorité de santé sur la prise en charge thérapeutique de la polyarthrite rhumatoïde en pratique courante
30. Mise en œuvre, en situation professionnelle, des recommandations de la HAS, par la méthode du test de concordance de script combinée à l’analyse actualisée de la littérature. Application à la polyarthrite rhumatoïde
31. Abatacept therapy and safety management
32. Potential Benefit of Rituximab in Rhupus Patients From a Single-Center
33. AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review
34. A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs
35. Les applications en rhumatologie : perspectives
36. La transcriptomique en 2011: les principales applications ?
37. Les biomarqueurs : la transcriptomique en 2011, comment cela fonctionne-t-il ?
38. L’infliximab à 3 mg/kg en dose initiale dans la spondylarthrite active résistante aux traitements habituels est efficace, bien toléré et moins coûteux
39. Rheumatologic manifestations of sarcoidosis and increased risk of spondyloarthritis occurrence. A retrospective single center case-control study
40. Valvular and infection-associated risk factors as criteria to guide the use of echocardiography in patients with native joint infections
41. Anti-Carbamylated Fibrinogen Antibodies Might Be Associated With a Specific Rheumatoid Phenotype and Include a Subset Recognizing In Vivo Epitopes of Its γ Chain One of Which Is Not Cross Reactive With Anti-Citrullinated Protein Antibodies
42. Musculoskeletal Symptoms in Patients With Cryopyrin-Associated Periodic Syndromes: A Large Database Study
43. Polyarthrite rhumatoïde : définitions de la réponse, des différents niveaux d’activité et de la rémission
44. Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients
45. Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis
46. Un cas de maladie de Whipple mimant un syndrome auto-inflammatoire et révélée par une sévère insuffisance ventriculaire droite sous anakinra
47. Towards an individualised target concentration of adalimumab in rheumatoid arthritis
48. Maladie de Castleman chez deux patientes atteintes de spondyloarthrite traitées par anti Tumor Necrosis Factor-alpha
49. Association Between the Number of Comorbidities and the Risk of a Serious Infection in Rheumatoid Arthritis Treated by a First Biologic Agent
50. Castleman's disease in two patients with spondyloarthritis treated by Tumor Necrosis Factor-alpha antagonists
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.